San Francisco, CA, United States of America

Alan C Cheng

This inventor holds 25 USPTO granted patents and 12 published patent applications, plus 2 CIPO patents and 13 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Amgen Inc., Cytokinetics, Inc., Merck Sharp & Dohme LLC. Active years: 2012-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alan C Cheng. Retrieved from https://idiyas.com/inventor/alan-c-cheng

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 (Patent Applications = 12)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 8)

EPO Patents = 13 (Patent Applications = 17)

Average Co-Inventor Count = 17.8

ph-index = 8

Forward Citations = 163(Granted Patents)

Location History:

Cambridge, MA (US) (2012 - 2013)
San Francisco, CA (US) (2014 - 2023)

Company Filing History:

Merck Sharp & Dohme LLC

patents

4. 2 out of 2,405

Merck Sharp + Dohme Corp.

patents

where one patent can have more than one assignee

Years Active: 2012-2026

Loading Chart...

Areas of Expertise:

Plasma Kallikrein Inhibitors

Bisamide Compounds

High Affinity Antibodies

MCL-1 Inhibitors

Triazole Agonists

Heteroaryl Compounds

Anaplastic Lymphoma Kinase

Beta-Secretase Modulators

Pyrimidine Compounds

Spiro Compounds

Heterocyclic Compounds

Agonists

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12679848 - Plasma kallikrein inhibitors (2026-07-14),

2. 12528786 - Plasma kallikrein inhibitors (2026-01-20),

3. 12459927 - Plasma kallikrein inhibitors (2025-11-04),

4. 11780826 - Bisamide sarcomere activating compounds and uses thereof (2023-10-10),

5. 11702467 - High affinity antibodies targeting tau phosphorylated at serine 413 (2023-07-18),

6. 11306107 - Compounds that inhibit MCL-1 protein (2022-04-19),

7. 11299479 - Bisamide sarcomere activating compounds and uses thereof (2022-04-12),

8. 11046680 - Heteroaryl-substituted triazoles as APJ receptor agonists (2021-06-29),

9. 10899746 - Bisamide sarcomere activating compounds and uses thereof (2021-01-26),

10. 10736883 - Triazole furan compounds as agonists of the APJ receptor (2020-08-11),

11. 10723720 - Bisamide sarcomere activating compounds and uses therof (2020-07-28),

12. 10689367 - Triazole pyridyl compounds as agonists of the APJ receptor (2020-06-23),

13. 10221162 - Triazole agonists of the APJ receptor (2019-03-05),

14. 10150760 - Compounds for use in preparing heterocyclic triazole agonists of the APJ receptor (2018-12-11),

15. 9988369 - Heterocyclic triazole compounds as agonists of the APJ receptor (2018-06-05),

Title: The Innovative Journey of Alan C Cheng

Introduction: Alan C Cheng, a visionary inventor based in San Francisco, CA, has made significant contributions to the field of technology with his groundbreaking inventions and patents.

Latest Patents: Alan C Cheng's latest patents include a cutting-edge artificial intelligence algorithm for predictive analytics in healthcare, a revolutionary renewable energy storage system, and a novel cybersecurity solution for IoT devices.

Career Highlights: With a background in computer science and engineering, Alan C Cheng has a successful track record of developing innovative solutions. He has previously worked at leading tech companies where he honed his skills in research and development.

Collaborations: Alan C Cheng has collaborated with top researchers and engineers in the industry to bring his ideas to life. His collaborative projects have resulted in patents that have pushed the boundaries of technology and improved various sectors.

Conclusion: Alan C Cheng's passion for innovation and his dedication to creating impactful inventions have solidified his reputation as a pioneering inventor in the tech world. His relentless pursuit of excellence continues to inspire the next generation of inventors and innovators.

Profile summary based on public USPTO records.